Entact Bio Emerges With $81M to Play Matchmaker to Protein-Enhancing Drugs
Taking the opposite approach of targeted protein degradation, biotech company Entact Bio is developing medicines that stabilize proteins and even enhances their function. This approach that could apply to cancer and certain rare diseases and Entact's $81 million in Series A financing enables it to work on multiple programs in parallel.
Source: medcitynews.com